For investors who can tolerate high risk I am
recommending biotech stocks Northwest Biotherapeutics (NWBO) and TG Therapeutics (TGTX). Both companies are developing cancer
treatments that are showing very promising efficacy with excellent safety profiles. Both
these stocks have an enormous market potential while their current share prices are beaten down in
value. With clinical successes in 2017 & 2018 both these stocks have potential to become multi-baggers.
Yes, NWBO & TGTX are high risk stocks. And as you mentioned it may be a profitable stocks in future. All investors of biotechstocks search for such stocks.
ReplyDeleteHaim,
ReplyDeleteTGTX has had a really nice start to 2017, positive Phase3 data in high-risk rCLL has changed investor sentiment here. More catalysts are around the corner for this stock and I see much more upside potential for 2017.
NWBO has not hit its stride, their Phase3 is taking longer than I expected to read-out. Raising funds to continue operations and the associated dilution are now plaguing this stock. With positive Phase3 data in 2H17 NWBO can still be a massive winner.
Haim, Any concerns and insight on TGTX short interest? Crazy how much is short. I think hedge funds are controlling the price since there is risk implied until FDA approval. Great science and safety should prevail.
ReplyDeleteMarca2018,
ReplyDeleteI think the markets are backing TGTX's Cart-T competitors that's why we have a high and increasing short interest.
I am not worried this is a long-term Hold for me. TGTX's treatments look to have a best-in-class safety profiles and certainly they're safer than Car-ts. Efficacy is also very promising.
I am confident the markets will get behind us as more clinical trial data becomes available. GL